Related Experiment Video

Updated: Sep 27, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

Therapeutic impact and routine application of next-generation sequencing: A single institute study

Rocío Hernández-Pacheco Acosta1, María Del Carmen Damas Fuentes1, Nicolás Gallego Pena1

  • 1Department of Medical Oncology, Virgen Macarena University Hospital, 41009 Seville, Spain.

Biomedical Reports
|April 7, 2022
PubMed

Insights

Genomic sequencing, or next-generation sequencing (NGS), identifies actionable targets in cancer patients. This approach offers new therapeutic options for individuals with limited treatment alternatives.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Genomic sequencing of tumor tissues reveals actionable gene aberrations.
  • These aberrations hold diagnostic and therapeutic significance, potentially guiding cancer management.
  • Establishing indications and limitations for genomic sequencing in clinical practice is crucial.

Purpose of the Study:

  • To analyze patients eligible for next-generation sequencing (NGS) with limited therapeutic options.
  • To identify molecular targets and assess their therapeutic impact in this patient cohort.
  • To evaluate the utility of NGS in guiding cancer treatment decisions.

Main Methods:

  • Retrospective review of 26 cancer patients who underwent NGS analysis.
  • Analysis conducted at Virgen Macarena Hospital between January 2017 and December 2019.
  • Identification of actionable molecular alterations and subsequent treatment guided by NGS findings.

Main Results:

  • Actionable molecular alterations were identified in 20 out of 26 patients (77%).
  • Four patients received treatment guided by the NGS results.
  • NGS identified potential therapeutic targets in a significant proportion of patients with limited options.

Conclusions:

  • Next-generation sequencing (NGS) presents a novel opportunity for personalized cancer treatment.
  • Patients with limited therapeutic alternatives, due to diagnosis, disease progression, or resistance, are suitable candidates for NGS.
  • NGS-guided therapy can offer new treatment avenues for challenging cancer cases.
Keywords:
cancer of unknown primarydriver mutationsnext-generation sequencingtumor-agnostic treatment

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
93.1K
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
759.5K